FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205299447> ?p ?o ?g. }

• W4205299447 endingPage "S22" @default.
• W4205299447 startingPage "S22" @default.
• W4205299447 abstract "Sunitinib, a first-line (1L) treatment option for patients with metastatic renal cell carcinoma (mRCC), has a standard dosing schedule of 50mg once daily for a 4-week on 2 weeks off cycle (4:2). However, studies with small selected populations have reported improved outcomes with schedule alterations. We investigated the impact of different 1L sunitinib dosing schedules on treatment duration and survival in a real-world setting for a nationwide Swedish mRCC cohort. This was a retrospective analysis utilizing the population based Swedish Health Data Registers. The cohort included all mRCC patients aged ≥ 18 years with ≥ 1 filled prescription from July 2005–December 2019. Three dosing schedules were analyzed: starting on 4:2, starting on 2 weeks on 1 week off (2:1) and starting on 4:2 then switching to 2:1 (SW). A grace period of 90 days was permitted between filled prescriptions to allow for medication accumulated from overlapping prescriptions; patients exceeding this period were defined as non-persistent. Outcomes were time-to-treatment discontinuation (TTD) and overall survival (OS) as analyzed by Kaplan-Meier methods. 1095 patients with mRCC were identified initiating 1L sunitinib (2:1, n=320: SW, n=71: 4:2, n=704) and baseline characteristics including, age, gender, and age at RCC-diagnosis were similar between subgroups. TTD (95% CI) was significantly different between subgroups (p<0.001) with median at 6.20 (5.6, 7.2), 13.91 (8.1, 20.6) and 4.55 (4.3, 5.6) months for 2:1, SW and 4:2 dosing, respectively. OS (95% CI) also differed significantly between subgroups (p<0.001) with median at 21.79 (18.1, 26.1), 32.20 (25.1, 48.3) and 13.48 (12.3, 15.8) months for 2:1, SW and 4:2 dosing, respectively. Modified 1L sunitinib schedules were associated with prolonged treatment duration and OS. The greatest benefit was observed in patients who switched from 4:2 to 2:1; however, data from patients starting 2:1 dosing was comparatively immature." @default.
• W4205299447 created "2022-01-25" @default.
• W4205299447 creator A5026551302 @default.
• W4205299447 creator A5027450859 @default.
• W4205299447 creator A5056442029 @default.
• W4205299447 creator A5056448035 @default.
• W4205299447 creator A5060308735 @default.
• W4205299447 date "2022-01-01" @default.
• W4205299447 modified "2023-09-26" @default.
• W4205299447 title "POSA26 Sunitinib Treatment Modification in First-line Metastatic Renal Cell Carcinoma: Analysis of a Real-World Swedish Cohort" @default.
• W4205299447 doi "https://doi.org/10.1016/j.jval.2021.11.099" @default.
• W4205299447 hasPublicationYear "2022" @default.
• W4205299447 type Work @default.
• W4205299447 citedByCount "0" @default.
• W4205299447 crossrefType "journal-article" @default.
• W4205299447 hasAuthorship W4205299447A5026551302 @default.
• W4205299447 hasAuthorship W4205299447A5027450859 @default.
• W4205299447 hasAuthorship W4205299447A5056442029 @default.
• W4205299447 hasAuthorship W4205299447A5056448035 @default.
• W4205299447 hasAuthorship W4205299447A5060308735 @default.
• W4205299447 hasBestOaLocation W42052994471 @default.
• W4205299447 hasConcept C126322002 @default.
• W4205299447 hasConcept C143998085 @default.
• W4205299447 hasConcept C167135981 @default.
• W4205299447 hasConcept C201903717 @default.
• W4205299447 hasConcept C2426938 @default.
• W4205299447 hasConcept C2777288759 @default.
• W4205299447 hasConcept C2777472916 @default.
• W4205299447 hasConcept C2778715236 @default.
• W4205299447 hasConcept C2779490328 @default.
• W4205299447 hasConcept C2908647359 @default.
• W4205299447 hasConcept C71924100 @default.
• W4205299447 hasConcept C72563966 @default.
• W4205299447 hasConcept C98274493 @default.
• W4205299447 hasConcept C99454951 @default.
• W4205299447 hasConceptScore W4205299447C126322002 @default.
• W4205299447 hasConceptScore W4205299447C143998085 @default.
• W4205299447 hasConceptScore W4205299447C167135981 @default.
• W4205299447 hasConceptScore W4205299447C201903717 @default.
• W4205299447 hasConceptScore W4205299447C2426938 @default.
• W4205299447 hasConceptScore W4205299447C2777288759 @default.
• W4205299447 hasConceptScore W4205299447C2777472916 @default.
• W4205299447 hasConceptScore W4205299447C2778715236 @default.
• W4205299447 hasConceptScore W4205299447C2779490328 @default.
• W4205299447 hasConceptScore W4205299447C2908647359 @default.
• W4205299447 hasConceptScore W4205299447C71924100 @default.
• W4205299447 hasConceptScore W4205299447C72563966 @default.
• W4205299447 hasConceptScore W4205299447C98274493 @default.
• W4205299447 hasConceptScore W4205299447C99454951 @default.
• W4205299447 hasIssue "1" @default.
• W4205299447 hasLocation W42052994471 @default.
• W4205299447 hasOpenAccess W4205299447 @default.
• W4205299447 hasPrimaryLocation W42052994471 @default.
• W4205299447 hasRelatedWork W2072245035 @default.
• W4205299447 hasRelatedWork W2182272419 @default.
• W4205299447 hasRelatedWork W2334045336 @default.
• W4205299447 hasRelatedWork W2480565470 @default.
• W4205299447 hasRelatedWork W2791305060 @default.
• W4205299447 hasRelatedWork W2971476881 @default.
• W4205299447 hasRelatedWork W3151554875 @default.
• W4205299447 hasRelatedWork W4205243027 @default.
• W4205299447 hasRelatedWork W4205299447 @default.
• W4205299447 hasRelatedWork W4361881780 @default.
• W4205299447 hasVolume "25" @default.
• W4205299447 isParatext "false" @default.
• W4205299447 isRetracted "false" @default.
• W4205299447 workType "article" @default.